A director at GL Events sold 1,516 shares at 32.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Nous avons sélectionné 10 graphiques afin d’identifier les principaux drivers du secteur. Les Capex sont attendus en repli de 1.5% en 2026 après un rebond de 70% depuis le point bas de 2020. Cette baisse proviendra essentiellement du marché US (plus forte discipline compte tenu de points morts plus élevés). Nous privilégions SBM Offshore (Surperformance, OC 45 €), Vallourec (Surperformance, OC 22 € vs 20.8 €) et Technip Energies (Surperformance, OC 49 €) et adoptons une opinion plus prudente sur...
For the start of 2026, we have selected ten charts to identify the sector's main drivers. Capex is expected to fall by 1.5% in 2026 after a 70% rebound from the low point of 2020. This reduction will mainly come from the US market (greater discipline due to higher breakeven points). At this point in the year, we prefer SBM Offshore (Outperform, target price € 45), Vallourec (Outperform, target price € 22 vs € 20.8) and Technip Energies (Outperform, target price € 49) and have adopted a more caut...
Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: ...
Transgene présente son calendrier de communication financière pour 2026 Strasbourg (France), le 4 février 2026, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd'hui son calendrier de communication financière pour 2026 et la date de son Assemblée générale annuelle : 24 mars 2026 : Résultats annuels de l’exercice 2025 29 avril 2026 : Résultats financiers du premier trimestre 2026 13 mai 2026 : Assembl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.